MX2021014357A - Metodos y formulaciones para tratar trastornos de la vision. - Google Patents

Metodos y formulaciones para tratar trastornos de la vision.

Info

Publication number
MX2021014357A
MX2021014357A MX2021014357A MX2021014357A MX2021014357A MX 2021014357 A MX2021014357 A MX 2021014357A MX 2021014357 A MX2021014357 A MX 2021014357A MX 2021014357 A MX2021014357 A MX 2021014357A MX 2021014357 A MX2021014357 A MX 2021014357A
Authority
MX
Mexico
Prior art keywords
methods
formulations
vision disorders
treating vision
combinations
Prior art date
Application number
MX2021014357A
Other languages
English (en)
Inventor
David F Woodward
Weizhen Wang
Original Assignee
Jenivision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenivision Inc filed Critical Jenivision Inc
Publication of MX2021014357A publication Critical patent/MX2021014357A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan formulaciones oculares que comprenden compuestos agonistas del receptor adrenérgico ß de acción prolongada (LABA), antagonistas muscarínicos de acción prolongada (LAMA) y combinaciones de estos. También se proporcionan métodos para tratar trastornos de la visión con LABA, LAMA y combinaciones de estos.
MX2021014357A 2019-06-10 2020-06-09 Metodos y formulaciones para tratar trastornos de la vision. MX2021014357A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859682P 2019-06-10 2019-06-10
PCT/US2020/036775 WO2020251926A1 (en) 2019-06-10 2020-06-09 Methods and formulations for treating vision disorders

Publications (1)

Publication Number Publication Date
MX2021014357A true MX2021014357A (es) 2022-02-22

Family

ID=73782087

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014357A MX2021014357A (es) 2019-06-10 2020-06-09 Metodos y formulaciones para tratar trastornos de la vision.

Country Status (9)

Country Link
US (1) US20220218630A1 (es)
EP (1) EP3979996A4 (es)
JP (1) JP2022536460A (es)
KR (1) KR20220018484A (es)
CN (1) CN113993511A (es)
AU (1) AU2020290414A1 (es)
CA (1) CA3142885A1 (es)
MX (1) MX2021014357A (es)
WO (1) WO2020251926A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022314016B2 (en) * 2021-07-20 2024-05-09 Eye Hospital, Wenzhou Medical University Method for treating myopia with vinpocetine
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1731101A (en) * 1999-12-07 2001-06-18 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
EP1397132A4 (en) * 2001-05-25 2006-12-13 Valley Forge Pharmaceuticals I OPHTHALMIC PIRENZEPINE GEL
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
US11642350B2 (en) * 2017-03-23 2023-05-09 Singapore Health Services Pte Ltd Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient

Also Published As

Publication number Publication date
CN113993511A (zh) 2022-01-28
EP3979996A1 (en) 2022-04-13
US20220218630A1 (en) 2022-07-14
AU2020290414A1 (en) 2021-12-02
CA3142885A1 (en) 2020-12-17
KR20220018484A (ko) 2022-02-15
WO2020251926A1 (en) 2020-12-17
EP3979996A4 (en) 2023-06-14
JP2022536460A (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
MD3788044T2 (ro) Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
MX2021001957A (es) Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MX2021014357A (es) Metodos y formulaciones para tratar trastornos de la vision.
WO2005123093A3 (en) Ophthalmic formulations including selective alpha 1 antagonists
EP3870170A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES
EP4212532A3 (en) Mitragynine analogs and uses thereof
MX359668B (es) Derivados de retinal y metodos para su uso en el tratamiento de trastornos visuales.
CL2021002651A1 (es) Métodos de tratamiento del linfoma no hodgkin usando 2- (2,6-dioxopiperidin-3-yl) -4 - ((2-fluoro-4 - ((3-morfolinoazetidin-1-yl) metil) bencil) amino) isoindolina- 1,3-diona
MX2020013004A (es) Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
EP4302761A3 (en) Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX2020013116A (es) Sales y cristales novedosos.
MX2022006807A (es) Análogos de rapamicina y usos de estos.
MX2020011873A (es) Nuevos derivados de quinolina.
MY197171A (en) Compounds and methods for the treatment of parasitic diseases
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2020008359A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
ZA201907101B (en) Methods of preventing or treating ophthalmic diseases
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2022002838A (es) Compuesto heterocíclico aromático que tiene estructura tricíclica, y método de preparación y aplicación del mismo.
EP3988075A4 (en) DRUG SOLUTION TO DELIVER SETTING TOOL, DRUG SOLUTION TO DELIVER SETTING KIT, AND DRUG SOLUTION TO DELIVER SETTING METHOD USING THE SAME TOOL AND KIT